Mast-Cell Sarcoma Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 24, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Mast-Cell Sarcoma. It connects disease context, epidemiology, target mechanism, clinical competition, transactions, unmet need and market attractiveness for portfolio and partnering decisions.

Executive assessment

Mast-Cell Sarcoma receives a directional strategic score of 69/100, combining unmet need (83/100), competitive intensity (62/100, where higher means more competition) and market attractiveness (74/100). The score is a transparent prioritization aid, not a revenue forecast, clinical recommendation or investment conclusion.

Disease background and strategic definition

A unifocal malignant tumor that consists of atypical pathological MAST CELLS without systemic involvement. It causes local destructive growth in organs other than in skin or bone marrow.

The reproducible entity is Patsnap disease ID c11966b529134a0a913945c3a81d343e with MeSH identifier D012515. Stable identifiers are important because rare and precision-defined diseases often carry historical labels, gene-defined subtypes and overlapping syndromic names.

A credible target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, treatment setting, acceptable safety and endpoint. A broad label may inflate theoretical market size while weakening biological signal, trial interpretability and recruitment feasibility. The first population should be narrow enough for coherent biology but large enough for execution.

The care pathway should be mapped from symptom recognition through referral, diagnostic testing, treatment initiation and longitudinal monitoring. Diagnostic delay, limited specialist centers and fragmented testing can constrain both trial enrollment and commercial access. These bottlenecks deserve explicit operational assumptions.

Epidemiology and disease burden

Epidemiology evidence 1: WHO report on cancer: setting priorities, investing wisely and providing care for all Making the case

### Chart Data Transcription Report 1. Basic Chart Information * Chart Title: Fig. 1.1. Estimated global burden of cancer in 2018 * Chart Type: Comparative Data Table with associated visualization * Contextual Summary: This chart presents the estimated global burden of various cancer types in 2018 for males, detailing incident cases and their respective percentages. It highlights the leading cancer types contributing to the global cancer burden. 2. Chart Structure and Elements * Axes/Headers: * Row Headers: Cancer type (Lung, Prostate, Colorectum, Stomach, Liver, Bladder, Oesophagus, Non-Hodgkin lymphoma, Kidney, Leukaemia, Other cancers) * Column Headers: Incident cases, Percentage (implied) * Legend/Groups: The visualization on the right shows a silhouette of a "Male" and a series of red circles of varying sizes, which visually represent the proportion of incident cases for each listed cancer type, corresponding to the percentages. Larger circles represent higher percentages. * Notes and Footnotes: No specific notes or footnotes are provided within the image. 3. Detailed Data Transcription This table provides the estimated global incident cases and their percentages for various cancer types in 2018 among males. * Lung cancer: * Incident cases: 1,368,524 * Percentage of total incident cases: 14.5% * Prostate cancer: * Incident cases: 1,276,106 * Percentage of total incident cases: 13.5% * Colorectum cancer: * Incident cases: 1,026,215 * Percentage of total incident cases: 10.9% * Stomach cancer: * Incident cases: 683,754 * Percentage of total incident cases: 7.2% * Liver c

Review the epidemiology source

Epidemiology evidence 2: Cancer Statistics, 2000

In the year 2000, we estimate that about 1,220,100 new cases of invasive cancer will be diagnosed in the US (Table 1). This estimate does not include carcinoma in situ of any site except urinary bladder, and it does not include basal and squa- mous cell cancers of the skin. Approxi- mately 1.3 million cases of basal and squamous cell skin cancers, 42,600 cases of breast carcinoma in situ, and 28,600 cases of in situ melanoma are expected to be newly diagnosed in 2000. Among men, the most common can- cers in 2000 are expected to be cancers of the prostate, lung and bronchus, and colon and rectum (Fig. 1). The prostate is the leading site for cancer incidence, account- ing for 29% of new cancer cases in men. This year, 180,400 new cases of prostate cancer are expected to be diagnosed. Among women, the three most com- monly diagnosed cancers are expected to be cancers of the breast, lung and bronchus, and colon and rectum (Fig. 1). Cancers occurring at these sites are ex- pected to account for over 50% of new cancer cases in women. Breast cancer alone is expected to account for 182,800 new cancer cases (30%) in 2000. TRENDS IN CANCER INCIDENCE For all sites combined, SEER cancer inci- dence rates appeared to peak in 1992 and decreased an average of -2.2% per year from 1992 to 1996.9 Similar declines have been seen recently for specific leading cancer sites (Figs. 3 and 4). Breast cancer incidence rates have remained approximately level during the 1990s; however, they appear to be de- creasing in younger women. Decreases in colon and rectum cancer incidence rates began in the mi

Review the epidemiology source

Epidemiology evidence 3: Cancer Statistics: Breast Cancer In Situ

Cancer Statistics: Breast Cancer In Situ CA CANCER J CLIN 2015;65:481–495 Cancer Statistics: Breast Cancer In Situ Elizabeth M. Ward, PhD1*; Carol E. DeSantis, MPH2; Chun Chieh Lin, PhD, MBA2; Joan L. Kramer, MD3; Ahmedin Jemal, DVM, PhD4; Betsy Kohler, MPH5; Otis W. Brawley, MD6; Ted Gansler, MD, MBA, MPH7 An estimated 60,290 new cases of breast carcinoma in situ are expected to be diagnosed in 2015, and approximately 1 in 33 women is likely to receive an in situ breast cancer diagnosis in her lifetime. Although in situ breast cancers are relatively com- mon, their clinical significance and optimal treatment are topics of uncertainty and concern for both patients and clinicians. In this article, the American Cancer Society provides information about occurrence and treatment patterns for the 2 major sub- types of in situ breast cancer in the United States—ductal carcinoma in situ and lobular carcinoma in situ—using data from the North American Association of Central Cancer Registries and the 13 oldest Surveillance, Epidemiology, and End Results regis- tries. The authors also present an overview of in situ breast cancer detection, treatment, risk factors, and prevention and dis- cuss research needs and initiatives. CA Cancer J Clin 2015;65:481-495. V C 2015 American Cancer Society. Keywords: breast neoplasms, epidemiology, race/ethnicity-specific incidence, ductal carcinoma in situ, lobular carcinoma in situ, lobular neoplasia Introduction Excluding skin cancers, invasive breast cancer is the most common cancer diagnosed among women in the United States, with an estimated 23

Review the epidemiology source

Translate epidemiology into an addressable-patient funnel: total affected population → diagnosed patients → clinically eligible segment → treated patients → realistically accessible patients. Incidence, point prevalence and lifetime prevalence cannot be substituted for one another, and incompatible case definitions should not be pooled.

For Mast-Cell Sarcoma, quantify diagnostic yield, age and severity distribution, referral-center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges. Each parameter should have a source, access date and explanation of how it maps to the intended clinical population.

Population concentration can materially change strategy. A small but well-defined group managed in a limited number of centers may be operationally attractive, while a larger but poorly diagnosed population may require extensive testing and education. Epidemiology must therefore connect to the real patient journey.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: irreversible progression, incomplete control, treatment-limiting toxicity, weak durability, burdensome administration, delayed diagnosis or lack of options for a biomarker-defined subgroup. Disease severity alone does not prove that a new program can demonstrate clinically meaningful benefit.

A strong Mast-Cell Sarcoma thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit can be measured within a feasible time horizon and whether natural-history variability can be controlled. Functional measures, patient-reported outcomes and resource use may complement biomarkers.

Development should proceed through evidence gates. Establish phenotype and natural history, demonstrate target engagement, observe a pharmacodynamic response, show an interpretable clinical signal and only then scale toward registrational development. Pre-agreed stop criteria protect capital and improve learning from negative results.

Target mechanism anchor: IL-1β

Potent pro-inflammatory cytokine (PubMed:10653850, PubMed:12794819, PubMed:28331908, PubMed:3920526). Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production (PubMed:3920526). Promotes Th17 differentiation of T-cells. Synergizes with IL12/interleukin-12 to induce IFNG synthesis from T-helper 1 (Th1) cells (PubMed:10653850). Plays a role in angiogenesis by inducing VEGF production synergistically with TNF and IL6 (PubMed:12794819). Involved in transduction of inflammation downstream of pyroptosis: its mature form is specifically released in the extracellular milieu by passing through the gasdermin-D (GSDMD) pore (PubMed:33377178, PubMed:33883744). Acts as a sensor of S.pyogenes infection in skin: cleaved and activated by pyogenes SpeB protease, leading to an inflammatory response that prevents bacterial growth during invasive skin infection (PubMed:28331908).

The mechanism anchor is IL1B. It is a pathway hypothesis, not a claim that every Mast-Cell Sarcoma patient is target-dependent. Translational work should establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and a therapeutic window.

Critical experiments include orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit on-target and off-target safety testing. Human evidence should carry greater weight than model-only observations. Related clinical failures should be examined for exposure, population and endpoint lessons.

A go decision requires a complete chain: relevant target biology, achievable modulation at tolerated exposure, measurable pharmacodynamic change and a plausible bridge to clinical benefit. Missing links should trigger targeted experiments rather than narrative confidence.

Clinical development and competitive landscape

The focused query returned 21 registered studies. Recent sampled records include:

• CTRI/2026/01/100522 — Role of combination of Marich and Goghrit in Patients Suffering from Sheetpitta; Not Yet Recruiting; Not Applicable; sponsor not stated; enrollment 60.
• NCT07143669 — Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations (POLARIS); Recruiting; Not Applicable; sponsor Blueprint Medicines Corp.; enrollment 750.
• NCT06186856 — Epidemiological Data on Mast Cell Pathologies in France (DATAMAST); Recruiting; Not Applicable; sponsor Imagine Institute of Genetic Diseases; enrollment 13000.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies from one asset can inflate activity. Normalize every record by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact disease subtype.

Competitive strategy should compare against the likely future standard at launch. Whitespace can arise from earlier treatment, genotype selection, improved durability, lower monitoring, safer chronic use, simpler administration or a rational combination. The differentiation claim must be visible in protocol design, not deferred to post hoc interpretation.

Recruitment risk is a core strategic variable. Site density, diagnostic testing, travel burden, competing protocols and screen-failure rates should inform country and center selection. Natural-history work can reduce uncertainty but cannot replace a controlled efficacy strategy when outcomes are variable.

Transaction activity and partnering attractiveness

No directly matched 2023–2026 transaction was returned. This may reflect limited partnering, broader transaction labels or asset-level indexing. Add target- and asset-based comparable searches before valuation.

Headline transaction value is rarely directly comparable. Separate upfront payments, milestones, royalties, options, bundled programs, platform rights and geographic scope. A useful comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical plan, intellectual property, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Outreach is most effective around a credible catalyst that retires material risk.

Low direct deal activity can represent whitespace, but it can also signal difficult science or economics. Broader therapeutic-area transactions should be used only when their relevance is explicit. Avoid assuming that all rare-disease transactions share the same valuation logic.

Market attractiveness and access

Market attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, administration setting, payer controls, alternatives, monitoring burden and geographic reimbursement. Patient count is only one driver. Reliable identification and a meaningful effect may outweigh a small population; fragmented diagnosis can undermine a larger one.

The commercial model should use scenario ranges for diagnosed prevalence, eligible share, launch timing, competitive entries, net price, persistence and penetration. Every assumption should be traceable. Refresh the model when new epidemiology, trial or deal evidence becomes available.

Payer research should begin before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Evidence may need quality of life, caregiver burden, hospital use, diagnostic costs or productivity outcomes. The value proposition should connect clinical effect to stakeholder-relevant outcomes.

Risks and decision gates

• Disease-definition risk: confirm a consistently diagnosed and recruitable population.
• Biology risk: demonstrate IL1B relevance in the selected phenotype.
• Translation risk: connect engagement to a biomarker and meaningful endpoint.
• Competition risk: refresh the landscape before every investment gate.
• Operational risk: validate sites, testing and screen-failure assumptions.
• Commercial risk: test pricing, access and adoption with clinicians and payers.
• Data risk: treat zero-result searches as prompts for broader queries, not proof of absence.

Recommended gates are population confirmation, human mechanism validation, differentiated target product profile, early proof of mechanism and scale-up only after biological, clinical, operational and commercial signals converge.

Strategic recommendation

Mast-Cell Sarcoma merits continued milestone-based evaluation. The opportunity is strongest if a phenotype or biomarker identifies patients with coherent biology, if IL1B modulation is measurable and if the proposed benefit remains differentiated against future care. Current evidence supports targeted diligence rather than unconditional investment.

The near-term business-development objective is a partner-ready thesis explaining the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scorecard offers a common comparison language while preserving evidence gaps and uncertainty.

Methodology and source note

This report was assembled on August 24, 2026 using Patsnap MCP tools in sequence: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and may change as databases update.

Ranking weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Rerun searches with synonyms, disease roll-ups, target names and asset filters before a transaction or portfolio commitment.

Conclusion

The key question for Mast-Cell Sarcoma is whether a biologically grounded therapy can deliver material patient benefit in an identifiable population and remain differentiated through launch. The evidence assembled here supplies a structured starting point, while the explicit gaps define the next diligence plan.